Abeona Therapeutics (ABEO) Cash & Equivalents (2010 - 2026)

Abeona Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $61.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 285.13% year-over-year to $61.4 million in Q1 2026; TTM through Mar 2026 was $61.4 million, a 285.13% increase from a year earlier, with the FY2025 full-year figure at $78.4 million, up 231.03% from the prior year.
• Cash & Equivalents fell to $61.4 million in Q1 2026 per ABEO's latest filing, from $78.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $163.5 million in Q2 2025 and bottomed at $338000.0 in Q1 2023.
• The 5-year median for Cash & Equivalents is $14.6 million (2022), against an average of $29.5 million.
• Across the five-year window, Cash & Equivalents tumbled 94.85% in 2024 and jumped 48283.14% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $14.6 million in 2022, then climbed by 1.76% to $14.8 million in 2023, then soared by 59.98% to $23.7 million in 2024, then surged by 231.03% to $78.4 million in 2025, then fell by 21.75% to $61.4 million in 2026.
• Per Business Quant, the three latest ABEO Cash & Equivalents figures stand at $61.4 million (Q1 2026), $78.4 million (Q4 2025), and $83.2 million (Q3 2025).